New mRNA HIV vaccines enter first human safety trial
NCT ID NCT07390474
First seen Feb 05, 2026
Summary
This early-stage trial tests two experimental mRNA vaccines (DV201P-RNA and DV202B1-RNA) designed to teach the body to make HIV-like proteins and trigger broadly neutralizing antibodies. The study enrolls 40 healthy adults without HIV to check safety and immune response. If the vaccines prove safe and generate the desired antibodies, it could pave the way for larger studies aiming to prevent HIV infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center VCRS (BIDMC VCRS Site # 32077)
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Columbia P&S CRS (Site ID: 30329)
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Penn Prevention CRS
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Hope Clinic of the Emory Vaccine Research Center; Emory University
RECRUITINGDecatur, Georgia, 30030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Ponce de Leon Center CRS
NOT_YET_RECRUITINGAtlanta, Georgia, 30308, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh CRS
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Rochester Vaccines to Prevent HIV Infection CRS
NOT_YET_RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA vaccines (DV201P-RNA and DV202B1-RNA) designed to teach the body to make HIV-like proteins and trigger immune cells that could neutralize the virus
What this could lead to
If successful, this could point toward a vaccine that trains the immune system to produce broadly neutralizing antibodies against HIV, a major step toward preventing infection.
What could go wrong
This is a very early (Phase 1) trial with only 40 healthy volunteers. It primarily checks safety and immune response, not whether the vaccine actually prevents HIV. Many early vaccines fail to show enough benefit in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.